GlaxoSmithKline | GSK - Interest Expense On Debt


GlaxoSmithKline reported GBP219M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Alcon AG USD 53M 1000K Jun/2026
Amgen USD 653M 94.99B Sep/2026
argenx SE USD 1000K 0 Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 97.5M 14.5M Sep/2026
Genmab DKK 139M 129M Jun/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 137M 33M Jun/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Orion EUR 300K 400K Sep/2026
Pfizer USD 662M 5M Sep/2026
Philips EUR 84M 1000K Sep/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Smith & Nephew USD 69M 1000K Dec/2025
UCB EUR 49M 29M Dec/2025